Tisotumab vedotin in recurrent or metastatic cervical cancer

被引：23

作者：

Bogani, Giorgio ^{[1
]}

Coleman, Robert L. ^{[2
]}

Vergote, Ignace ^{[3
]}

Raspagliesi, Francesco ^{[1
]}

Lorusso, Domenica ^{[4
]}

Monk, Bradley J. ^{[5
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori Milano, Milan, Italy

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Univ Hosp Leuven, Leuven, Belgium

[4] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy

[5] Creighton Univ, Univ Arizona, HonorHlth, Phoenix, AZ USA

来源：

CURRENT PROBLEMS IN CANCER | 2023年 / 47卷 / 03期

关键词：

Tisotumab vedotin; Cervical cancer; Survival; Immunotherapy; ADC; ANTIBODY-DRUG CONJUGATE; PREVIOUSLY TREATED RECURRENT; TISSUE FACTOR; CYTOPLASMIC DOMAIN; BEVACIZUMAB; INSIGHTS; VIIA;

D O I：

10.1016/j.currproblcancer.2023.100952

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tisotumab vedotin (TV) is an antibody-drug conjugate used for the treatment of adult patients with re-current or metastatic cervical cancer. TV comprised of a monoclonal antibody against tissue factor and monomethyl auristatin E (MMAE), a potent inhibitor of cell division. The innovaTV-201 and innovaTV-204/GO30xx/ENGOT-cx6 trials showed that TV has clinically meaningful and durable antitumor activity in pretreated patients with recurrent or metastatic cervical cancer. The innovaTV-204 trial showed that TV monotherapy resulted in an objective response rate of 24% (including 7% and 17% complete and par-tial responses, respectively). In September 2021, the US Food and Drugs Administration (FDA) granted accelerated approval to TV for the treatment of recurrent or metastatic cervical cancer patients with disease progression on or after chemotherapy. The ongoing randomized, open-label Phase 3 innovaTV-301/ENGOTcx12/GOG-30xx trial will assess the effect of TV in pre-treated recurrent or metastatic cervical cancer. Meanwhile, the phase 1b/2 trial ENGOT Cx8/GOG 3024/innovaTV-205 is testing other possible com-bination between TV and other treatments. TV is characterized by a promising antitumor activity and an acceptable safety profile. Moreover, the preliminary data highlighted the feasibility of using TV in first line. In the first line, TV in combination with carboplatin or pembrolizumab provides an ORR of 55% and 41%, respectively Although the effect of adding TV to the current standard of care in first-line (carboplatin plus pembrolizumab) is still under evaluation, we expected to observe impressive results in the cervical cancer population.

引用

页数：13

共 35 条

[1] Cervical Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines [J].

Abu-Rustum, Nadeem R. ;

Yashar, Catheryn M. ;

Bean, Sarah ;

Bradley, Kristin ;

Campos, Susana M. ;

Chon, Hye Sook ;

Chu, Christina ;

Cohn, David ;

Crispens, Marta Ann ;

Damast, Shari ;

Fisher, Christine M. ;

Frederick, Peter ;

Gaffney, David K. ;

Giuntoli, Robert, II ;

Han, Ernest ;

Huh, Warner K. ;

Lurain, John R., III ;

Mariani, Andrea ;

Mutch, David ;

Nagel, Christa ;

Nekhlyudov, Larissa ;

Fader, Amanda Nickles ;

Remmenga, Steven W. ;

Reynolds, R. Kevin ;

Sisodia, Rachel ;

Tillmanns, Todd ;

Ueda, Stefanie ;

Urban, Renata ;

Wyse, Emily ;

McMillian, Nicole R. ;

Motter, Angela D. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (06) :661-666

[2] Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells [J].

Albrektsen, T. ;

Sorensen, B. B. ;

Hjorto, G. M. ;

Fleckner, J. ;

Rao, L. V. M. ;

Petersen, L. C. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (08) :1588-1597

[3] BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer [J].

Bogani, Giorgio ;

Chiappa, Valentina ;

Bini, Marta ;

Ronzulli, Dominique ;

Indini, Alice ;

Conca, Elena ;

Raspagliesi, Francesco .

TUMORI JOURNAL, 2023, 109 (02) :244-248

[4] An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors [J].

Breij, Esther C. W. ;

de Goeij, Bart E. C. G. ;

Verploegen, Sandra ;

Schuurhuis, Danita H. ;

Amirkhosravi, Ali ;

Francis, John ;

Miller, Vibeke Breinholt ;

Houtkamp, Mischa ;

Bleeker, Wim K. ;

Satijn, David ;

Parren, Paul W. H. I. .

CANCER RESEARCH, 2014, 74 (04) :1214-1226

[5] Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis [J].

Bruni, Laia ;

Serrano, Beatriz ;

Roura, Esther ;

Alemany, Laia ;

Cowan, Melanie ;

Herrero, Rolando ;

Poljak, Mario ;

Murillo, Raul ;

Broutet, Nathalie ;

Riley, Leanne M. ;

de Sanjose, Silvia .

LANCET GLOBAL HEALTH, 2022, 10 (08) :E1115-E1127

[6] Updates in Systemic Treatment for Metastatic Cervical Cancer [J].

Chao, Angel ;

Lin, Cheng-Tao ;

Lai, Chyong-Huey .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (01) :1-13

[7] Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study [J].

Chung, Hyun Cheol ;

Ros, Willeke ;

Delord, Jean-Pierre ;

Perets, Ruth ;

Italiano, Antoine ;

Shapira-Frommer, Ronnie ;

Manzuk, Lyudmila ;

Piha-Paul, Sarina A. ;

Xu, Lei ;

Zeigenfuss, Susan ;

Pruitt, Scott K. ;

Leary, Alexandra .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (17) :1470-+

[8] Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor [J].

Cocco, Emiliano ;

Varughese, Joyce ;

Buza, Natalia ;

Bellone, Stefania ;

Glasgow, Michelle ;

Bellone, Marta ;

Todeschini, Paola ;

Carrara, Luisa ;

Silasi, Dan-Arin ;

Azodi, Masoud ;

Schwartz, Peter E. ;

Rutherford, Thomas J. ;

Pecorelli, Sergio ;

Lockwood, Charles J. ;

Santin, Alessandro D. .

BMC CANCER, 2011, 11

[9] Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study [J].

Coleman, Robert L. ;

Lorusso, Domenica ;

Gennigens, Christine ;

Gonzalez-Martin, Antonio ;

Randall, Leslie ;

Cibula, David ;

Lund, Bente ;

Woelber, Linn ;

Pignata, Sandro ;

Forget, Frederic ;

Redondo, Andres ;

Vindelov, Signe Diness ;

Chen, Menghui ;

Harris, Jeffrey R. ;

Smith, Margaret ;

Nicacio, Leonardo Viana ;

Teng, Melinda S. L. ;

Laenen, Annouschka ;

Rangwala, Reshma ;

Manso, Luis ;

Mirza, Mansoor ;

Monk, Bradley J. ;

Vergote, Ignace .

LANCET ONCOLOGY, 2021, 22 (05) :609-619

[10] Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer [J].

Colombo, N. ;

Dubot, C. ;

Lorusso, D. ;

Caceres, M., V ;

Hasegawa, K. ;

Shapira-Frommer, R. ;

Tewari, K. S. ;

Salman, P. ;

Usta, E. Hoyos ;

Yanez, E. ;

Gumus, M. ;

de Mendoza, M. Olivera Hurtado ;

Samouelian, V ;

Castonguay, V ;

Arkhipov, A. ;

Toker, S. ;

Li, K. ;

Keefe, S. M. ;

Monk, B. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (20) :1856-1867

← 1 2 3 4 →